CVAC stock icon



About: CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Employees: 1,100

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

4% more call options, than puts

Call options by funds: $1M | Put options by funds: $968K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.19% less ownership

Funds ownership: 9.84% [Q4 2023] → 7.65% (-2.19%) [Q1 2024]

2% less funds holding

Funds holding: 89 [Q4 2023] → 87 (-2) [Q1 2024]

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

42% less capital invested

Capital invested by funds: $92.7M [Q4 2023] → $53.8M (-$39M) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
Avg. target
High target

1 analyst rating

Leerink Partners
Mani Foroohar
Market Perform
25 Apr 2024

Financial journalist opinion

2 months ago
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strains For influenza A strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and age groups For influeSeasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults nza B strains, geometric mean titers were lower than those elicited by the licensed comparator vaccines, in line with expectations and other initial mRNA-based clinical flu development programs Further optimizations to enhance immune responses against influenza B strains will be tested in additional Phase 2 study Candidate showed acceptable safety profile, confirming previous findings that the proprietary platform elicits strong overall antibody titers at well-tolerated dose levels TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK.
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK